MMIL_en

13 Dec 2021 | Unclassified

MMIL A disease characterised by the multiplication of cancerous cells in the bone marrow, multiple myeloma affects around 4,000 new patients each year in France, for whom current treatments do not, in the majority of cases, provide a complete cure. The MMIL project...

CLUSTER_en

13 Dec 2021 | Unclassified

CLUSTER The accumulation of fluid in the serosa is an important event in the progression of adenocarcinoma. These malignant effusions are characterised by the presence of carcinoma cells. Their presence indicates disease progression and is associated with shorter...

DEMETEAR_en

13 Dec 2021 | Unclassified

DEMETEAR With an occurrence of approximately 2500 new cases per year in France, B-cell chronic lymphocytic leukaemia (CLL) is a major public health issue. The clinical management of patients, both in the first line and in relapse, has been revolutionised by the...

IMMUSPHINX_en

13 Dec 2021 | Unclassified

IMMUSPHINX: Targeting sphingolipid metabolism to improve the efficacy of immunotherapies in melanoma. Immune checkpoint inhibitors (ICIs) have shown an unprecedented and long-lasting anti-tumour response in patients with metastatic melanoma. To increase the proportion...

PIPgene_en

13 Dec 2021 | Unclassified

PIPgen: a new Innovative Training Network to put PI3K/PTEN related diseases under the spotlight PIPgen brings together 9 leading European basic and clinical institutions and 3 private companies experts in the PI3K/PTEN field, to train 15 researchers at the Phd level...

Pin It on Pinterest